Does Setmelanotide help with commonobesity? Grade D evidence

What the studies show

Not developed for obesity without a monogenic cause. Early-phase work in general obesity showed effects too small to pursue; no controlled trial supports the use and no regulator has approved it.

Animal studies, cell studies, or anecdotes only. This is where almost every viral peptide sits. Promising and proven are different words for a reason.

1
Imcivree (setmelanotide) — European public assessment report.EMA, 2021 onwardLicensed indications; genetic confirmation required.

In context

Setmelanotide is a cyclic analogue of α-MSH that activates the MC4 receptor, the brain's main satiety switch. In people whose obesity is caused by rare mutations upstream of that receptor — POMC, PCSK1 or LEPR deficiency, or Bardet-Biedl syndrome — it restores the signal: 80% of POMC-deficient and 45% of LEPR-deficient patients lost at least a tenth of their body weight in a year, with hunger scores falling by a quarter to a half. Those trials had ten and eleven participants. In obesity that follows damage to the hypothalamus, a 120-person randomised trial found BMI fell 16.5% against a 3.3% rise on placebo; Canada approved that use in September 2026. It has no role in common obesity.

Setmelanotide is approved (rx) — rare genetic obesity; hypothalamic obesity in canada. Legal status differs by country — see the regulation section or the jurisdiction pages.

Questions

Is Setmelanotide proven to help with commonobesity?

No. There is no human evidence for it (No approved use; early trials only); the claim rests on animal or cell studies and LYO grades it D.

What studies are behind the grade?

Not developed for obesity without a monogenic cause. Early-phase work in general obesity showed effects too small to pursue; no controlled trial supports the use and no regulator has approved it.

Is Setmelanotide approved for this?

Setmelanotide is an approved medicine (Approved (Rx) — rare genetic obesity; hypothalamic obesity in Canada); whether this particular outcome is a licensed indication is stated on the compound page's regulation section.

Other outcomes for Setmelanotide

BWeight loss in POMC / LEPR deficiency obesity2 single-arm phase 3 trials (n=10, n=11) with 8-wk placebo withdrawal
BHunger in POMC / LEPR deficiencySame trials
BWeight loss in Bardet-Biedl syndrome1 phase 3 with 14-wk placebo-controlled period (n=38)
BWeight loss in acquired hypothalamic obesity1 phase 3 RCT (TRANSCEND, n=120, 52 wk)
BAdverse effectsadverseSame trials

Written and maintained by LYO Research — how pages are written and checked. Reviewed 7 October 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →